Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 6Withdrawn 1Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Renal Cell 5Kidney Neoplasms 3Neoplasm Metastasis 2Glioblastoma 2Rectal Neoplasms 1Melanoma 1Lung Neoplasms 1Gliosarcoma 1Glioma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Carboplatin 18Radiotherapy 10Cisplatin 10Pemetrexed 8Paclitaxel 8durvalumab 6Magnetic Resonance Spectroscopy 6Gemcitabine 6Radiosurgery 5Nivolumab 5Etoposide 5pembrolizumab 4atezolizumab 4Surveys and Questionnaires 4Radiation 4Erlotinib Hydrochloride 4Docetaxel 4Taxes 3Standard of Care 3Specimen Handling 3Platinum 3Cetuximab 3Bronchoscopy 3Biopsy 3Bevacizumab 31,2-diaminocyclohexaneplatinum II citrate 3sapanisertib 2etoposide phosphate 2capmatinib 2Vinorelbine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lung Neoplasms × Sunitinib × Clear all
NCT00748163 2018-08-08

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

Masonic Cancer Center, University of Minnesota

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡